Oppenheimer lowered the firm’s price target on BridgeBio Oncology (BBOT) to $22 from $23 and keeps an Outperform rating on the shares after its wider than expected loss. The firm has also updated its operating expense estimates based on guidance from management, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBOT:
- BridgeBio Oncology reports Q3 EPS ($1.03), consensus (34c)
- BridgeBio Oncology’s Promising Preclinical Data and Strategic Advancements Justify Buy Rating
- BridgeBio Oncology announces new preclinical data on BBO-11818 study
- BridgeBio Oncology management to meet with Oppenheimer
- BridgeBio Oncology initiated with an Outperform at Leerink